公开(公告)号：US20240150318A1

公开(公告)日：2024-05-09

申请号：US18332851

申请日：2023-06-12

申请人： THE SCRIPPS RESEARCH INSTITUTE

发明人： Arnab K. Chatterjee ,  Jian Jeffrey Chen ,  Elshan Nakath ,  Alireza Rahimi ,  Anil Kumar Gupta ,  Gennadii Grabovyi ,  Katy Wilson ,  Sourav Ghorai ,  Armen Nazarian ,  James Pedroarena ,  Wrickban Mazumdar ,  Frank Weiss ,  Lirui Song ,  Malina A. Bakowski ,  Laura Riva ,  Karen Wolff ,  Case W. McNamara ,  Thomas F. Rogers ,  Jacqueline Malvin ,  Shuangwei Li ,  Sean Joseph ,  Ashley Woods ,  Yuyin Liu ,  Neechi Okwor

IPC分类号： C07D401/12 ,  A61K38/55 ,  C07D207/267 ,  C07D211/76 ,  C07D403/12 ,  C07D405/10 ,  C07D405/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D493/04

CPC分类号： C07D401/12 ,  A61K38/55 ,  C07D207/267 ,  C07D211/76 ,  C07D403/12 ,  C07D405/10 ,  C07D405/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D493/04

摘要： Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions:




wherein R1, R2, R3a, R3b, R4, R5, and A are defined in the present disclosure. The compounds are potent inhibitors of the main protease (Mpro) of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), and they are useful in treating or preventing COVID-19 in a subject.

公开(公告)号：US20230024012A1

公开(公告)日：2023-01-26

申请号：US17837814

申请日：2022-06-10

申请人： The Scripps Research Institute

发明人： Arnab K. Chatterjee ,  Jian Jeffrey Chen ,  Elshan Nakath ,  Alireza Rahimi ,  Anil Kumar Gupta ,  Gennadii Grabovyi ,  Katy Wilson ,  Sourav Ghorai ,  Armen Nazarian ,  James Pedroarena ,  Wrickban Mazumdar ,  Frank Weiss ,  Lirui Song ,  Malina A. Bakowski ,  Laura Riva ,  Karen Wolff ,  Case W. McNamara ,  Thomas F. Rogers ,  Jacqueline Malvin ,  Shuangwei Li ,  Sean Joseph ,  Ashley Woods ,  Yuyin Liu ,  Neechi Okwor

IPC分类号： C07D401/12 ,  C07D207/267 ,  C07D405/10 ,  C07D405/12 ,  C07D471/04 ,  C07D413/12 ,  C07D403/12 ,  C07D211/76 ,  C07D493/04 ,  C07D413/14 ,  A61K38/55

摘要： Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions: wherein R1, R2, R3a, R3b, R4, R5, and A are defined in the present disclosure. The compounds are potent inhibitors of the main protease (Mpro) of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), and they are useful in treating or preventing COVID-19 in a subject.

公开(公告)号：US11708348B2

公开(公告)日：2023-07-25

申请号：US17837814

申请日：2022-06-10

申请人： The Scripps Research Institute

发明人： Arnab K. Chatterjee ,  Jian Jeffrey Chen ,  Elshan Nakath ,  Alireza Rahimi ,  Anil Kumar Gupta ,  Gennadii Grabovyi ,  Katy Wilson ,  Sourav Ghorai ,  Armen Nazarian ,  James Pedroarena ,  Wrickban Mazumdar ,  Frank Weiss ,  Lirui Song ,  Malina A. Bakowski ,  Laura Riva ,  Karen Wolff ,  Case W. McNamara ,  Thomas F. Rogers ,  Jacqueline Malvin ,  Shuangwei Li ,  Sean Joseph ,  Ashley Woods ,  Yuyin Liu ,  Neechi Okwor

IPC分类号： C07D401/12 ,  A61K38/55 ,  C07D207/267 ,  C07D211/76 ,  C07D403/12 ,  C07D405/10 ,  C07D405/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D493/04

CPC分类号： C07D401/12 ,  A61K38/55 ,  C07D207/267 ,  C07D211/76 ,  C07D403/12 ,  C07D405/10 ,  C07D405/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D493/04

摘要： Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions:




wherein R1, R2, R3a, R3b, R4, R5, and A are defined in the present disclosure. The compounds are potent inhibitors of the main protease (Mpro) of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), and they are useful in treating or preventing COVID-19 in a subject.

公开(公告)号：US20230033285A1

公开(公告)日：2023-02-02

申请号：US17842415

申请日：2022-06-16

申请人： The Scripps Research Institute

发明人： Arnab K. Chatterjee ,  Jian Jeffrey Chen ,  Elshan Nakath ,  Alireza Rahimi ,  Anil Kumar Gupta ,  Gennadii Grabovyi ,  Katy Wilson ,  Sourav Ghorai ,  Armen Nazarian ,  James Pedroarena ,  Wrickban Mazumdar ,  Frank Weiss ,  Lirui Song ,  Malina A. Bakowski ,  Laura Riva ,  Karen Wolff ,  Case W. McNamara ,  Thomas F. Rogers ,  Jacqueline Malvin ,  Shuangwei Li ,  Sean Joseph ,  Ashley Woods ,  Yuyin Liu ,  Neechi Okwor

IPC分类号： C07D491/048 ,  C07D403/12 ,  C07D207/26 ,  C07D401/12 ,  C07D211/76 ,  C07D223/10 ,  C07D405/14 ,  C07D413/14 ,  C07D401/14 ,  C07D413/12 ,  A61P31/14

摘要： Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions: wherein R1, R2, R3a, R3b, R4, R5, and A are defined in the present disclosure. The compounds are potent inhibitors of the main protease (Mpro) of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), and they are useful in treating or preventing COVID-19 in a subject.